Biopharma
By
Could Roche’s New Vabysmo Data Redefine Long-Term Care in “wet” age-related macular degeneration (nAMD)?
Key Highlights Durability Demonstrated in AVONELLE-XRoche presented four-year data from AVONELLE-X at the Euretina 2025 Congress, showing that…
Could Lilly’s Olomorasib Breakthrough Designation Reshape the First-Line Treatment Landscape in KRAS G12C-Mutant Lung Cancer?
Key Takeaways Regulatory Milestone Positions Lilly in the KRAS Race The U.S. FDA has granted Breakthrough Therapy designation…
Is Novartis’ $5.2B siRNA Expansion with Argo Biopharma the Next Big Move in Cardiovascular?
Key Takeaways Expanding RNAi Leadership in Cardiovascular and Metabolic Diseases Novartis is reinforcing its strategic focus on cardiovascular…
Will Bayer’s Backing of RedHill’s Opaganib Open New Avenues in Precision Oncology?
Key Takeaways Bayer-Supported Trial Expands Opaganib’s Potential RedHill Biopharma’s collaboration with Bayer has taken center stage with the…
Can Gilead’s Twice-Yearly Yeytuo® (Lenacapavir) Redefine HIV Prevention Across Europe With Zero Infections in Phase 3 Trials?
Key Insights: A Historic European Approval That Expands Prevention Choices The European Commission granted marketing authorization for Gilead’s…
Can Amgen and Kyowa Kirin’s Rocatinlimab Redefine Atopic Dermatitis Care With Long-Term Safety and Sustained Efficacy in Over 2,600 Patients?
Key Insights: Breakthrough Data From ASCEND Long-Term Extension Amgen and Kyowa Kirin released top-line results from the global…
